Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Natera Inc. Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $72.00M), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 792.1× KraneShares Electric Vehicles and Future Mobility's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and Natera Inc. Common Stock for 0 Days on average.
| KARS | NTRA | |
|---|---|---|
Market Cap | $72.00M | $57.03B |
Volume | 31,901 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $425.64 |
52-Week Low | $26.72 | $179.42 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
